DiaCarta Overview

  • Founded
  • 2010
  • Status
  • Private
  • Employees
  • 12
  • Latest Deal Type
  • Debt - PPP
  • Investors
  • 3

DiaCarta General Information


Operator of translational genomics and personalized diagnostics company intended to provide treatments associated with precision molecular diagnostics. The company's technology focuses on genomic innovation through detection and amplification technologies and develops a range of cancer research and IVD products, specialized in genomic testing for biomarkers and offers clinical sample testing services, enabling healthcare practitioners to improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Primary Office
  • 2600 Hilltop Drive
  • Richmond, CA 94806
  • United States
+1 (800) 000-0000

DiaCarta Timeline

Financing RoundFinancing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

DiaCarta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Debt - PPP 14-May-2020 0000 Completed
2. Later Stage VC (Series B) 12-Feb-2018 0000 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 09-Jan-2015 $8M $8M Completed Product Development
To view DiaCarta’s complete valuation and funding history, request access »

DiaCarta Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Operator of translational genomics and personalized diagnostics company intended to provide treatments associated with p
Richmond, CA
12 As of 2015
000000000 - 0000


eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
Davis, CA
000000000 -


ididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco
Alameda, CA
00 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DiaCarta Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Expression Systems Corporation Davis, CA 000000000 -
00000000 Corporation Alameda, CA 00 000000000 -
00000000 Venture Capital-Backed Seattle, WA 00 0000 000000000 - 0000
0000000 00000000 Venture Capital-Backed Milpitas, CA 00 000.00 0000000000 000.00
000000 00000000 Formerly VC-backed Rutherford, NJ 000 000.00 000000000 000.00
You’re viewing 5 of 18 competitors. Get the full list »

DiaCarta Executive Team (6)

Name Title Board Seat Contact Info
Aiguo Zhang Ph.D Co-Founder, President & Chief Executive Officer
Laird Cagan Chief Financial Officer
Michael Powell Ph.D Chief Scientific Officer
Cynthia Virata Director of QA and Operations
Paul Okunieff MD Co-Founder, Medical Advisors & Chief Medical Officer
You’re viewing 5 of 6 executive team members. Get the full list »

DiaCarta Board Members (1)

Name Representing Role Since
Weixin Xu Ph.D BVCF Board Member 000 0000
To view DiaCarta’s complete board members history, request access »

DiaCarta Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DiaCarta Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fortune Fountain Capital PE/Buyout Minority 000 0000 000000 0
Global Healthcare Capital Real Estate Minority 000 0000 000000 0
BVCF Venture Capital Minority 000 0000 000000 0
To view DiaCarta’s complete investors history, request access »